Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | PTPRB | P23467 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 7/20 | 0.51 |
| ▸ | PPARD | Q03181 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312803 | 0.92 | MMP8 (0.62) | MMP8PTPRBPPARGALDH1A1TP53 | |
| SCHEMBL6711568 | 0.87 | MMP8 (0.57) | MMP8PTPRBPPARGPPARAALDH1A1 | |
| SCHEMBL16327191 | 0.87 | PTPRB (0.59) | MMP8PTPRBPPARGPPARDPPARA | |
| SCHEMBL9001515 | 0.87 | MAPT (0.54) | MMP8PTPRBALDH1A1PKM | |
| SCHEMBL28332902 | 0.86 | MMP8 (0.54) | MMP8PTPRBPPARGALDH1A1ESR1 | |
| SCHEMBL490486 | 0.86 | LDHA (0.69) | MMP8PPARGPPARDPPARAALDH1A1 | |
| SCHEMBL5800254 | 0.85 | MMP8 (0.55) | MMP8ALDH1A1TP53LDHANPY1R | |
| SCHEMBL20395698 | 0.84 | PPARG (0.62) | PTPRBPPARGPPARDPPARALDHA | |
| SCHEMBL7436472 | 0.84 | MMP8 (0.54) | MMP8PPARGALDH1A1TP53LDHA | |
| SCHEMBL27747 | 0.84 | MMP8 (0.58) | MMP8PTPRBALDH1A1TP53LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218106-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | EXXONMOBIL RES & ENG CO (US) | 2019-07-18 | — | — | US | disclosed |
| WO-2017095705-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218106-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | CD14, ERG28, DAP3 | MMP8 437/4885PTPRB 4067/4885PPARG 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.